Immunogenicity and safety of a 3-antigen hepatitis B vaccine vs a single-antigen hepatitis B vaccine: A phase 3 randomized clinical trial

Immunogenicity and safety of a 3-antigen hepatitis B vaccine vs a single-antigen hepatitis B vaccine: A phase 3 randomized clinical trial

<strong>Importance</strong> There is a need for improved immunogenicity of hepatitis B virus (HBV) vaccines among young adults with risk of infection. <br> <strong>Objectives</strong> To demonstrate manufacturing equivalence of a 3-antigen (3A) HBV vaccine, evaluate n...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs: Vesikari, T, Finn, A, van Damme, P, Leroux-Roels, I, Leroux-Roels, G, Segall, N, Toma, A, Vallieres, G, Aronson, R, Reich, D, Arora, S, Ruane, PJ, Cone, CL, Manns, M, Cosgrove, C, Faust, SN, Ramasamy, MN, Machluf, N, Spaans, JN, Yassin-Rajkumar, B, Anderson, D, Popovic, V, Diaz-Mitoma, F
Andere auteurs: CONSTANT Study Group
Formaat: Journal article
Taal:English
Gepubliceerd in: American Medical Association 2021

Gelijkaardige items